Anika Therapeutics Stock
Anika Therapeutics Stock
A loss of -1.230% shows a downward development for Anika Therapeutics.
Anika Therapeutics is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
With a target price of 15 € there is a hugely positive potential of 86.34% for Anika Therapeutics compared to the current price of 8.05 €.
Our community identified positive and negative aspects for Anika Therapeutics stock for the coming years. 1 users see the criterium "Brand" as a plus for the Anika Therapeutics stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Anika Therapeutics in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Anika Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Anika Therapeutics | -1.230% | -0.617% | -5.848% | -50.309% | -48.065% | -71.853% | -74.199% |
| Ardelyx Inc. | 0.230% | 2.840% | 4.881% | 6.187% | 6.465% | 184.469% | -6.409% |
| Krystal Biotech | 0.720% | 3.678% | 18.962% | 33.718% | 37.057% | 193.803% | - |
| Evolus Inc | 1.750% | -1.724% | -7.317% | -46.729% | -45.714% | -13.636% | 73.622% |
Comments
Anika Therapeutics (NASDAQ:ANIK) had its price target raised by analysts at Barrington Research from $15.00 to $16.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics (NASDAQ:ANIK) had its "outperform" rating reaffirmed by analysts at Barrington Research. They now have a $15.00 price target on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics Inc. (NASDAQ: ANIK) had its price target lowered by analysts at Barrington Research from $19.00 to $15.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
News
Anika (ANIK) Q2 Revenue Beats by 4%
Anika Therapeutics (NASDAQ:ANIK), a medical technology company focused on joint preservation and regenerative therapy products, released its earnings on July 30, 2025. The key news from the release
